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Zusammenfassung
Hintergrund: Die Cisplatin-basierte Kombinationschemo-
therapie wird aktuell als Standardtherapie für Patienten 
mit fortgeschrittenen Keimzelltumoren betrachtet. Vor-
angehende Studien zeigten auf, dass bei Patienten mit 
einer ausgedehnten Lungenmetastasierung eine mög-
liche Assoziation zwischen einer Induktionschemothe-
rapie und der Entwicklung eines sogenannten «Tumor-
 assoziierten» ARDS (acute respiratory distress syndrome) 
bestehen könnte. Fallbericht: Wir berichten über die 
 Kasuistik eines 19-jährigen Patienten mit metastasiertem 
Keimzelltumor des Hodens (Leber-, Lungen-, Lymphkno-
tenfiliae), der bereits während des ersten Zyklus einer 
Chemotherapie mit dem PEI-Regime (Cisplatin, Etoposid, 
Ifosfamid) rasch ein letales ARDS entwickelte. Schluss-
folgerung: Die zukünftige klinische Forschung sollte ver-
suchen, Risikofaktoren für die Entwicklung eines ARDS 
in dieser Patientenpopulation zu definieren und zudem 
auch innovative Strategien zur Prävention und Therapie 
dieser ARDS-Sonderform zu implementieren.
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Summary
Background: Cisplatin-based combination chemotherapy 
is regarded as standard of care for patients with ad-
vanced germ cell tumors. In patients with lung metas-
tases and a high tumor load, an association between in-
duction chemotherapy and the development of a ‘tumor-
associated’ acute respiratory distress syndrome (ARDS) 
has been hypothesized. Case Report: We report the clini-
cal course of a 19-year-old patient who rapidly developed 
fatal ARDS during the first cycle of chemotherapy using 
the PEI regimen (cisplatin, etoposide and ifosfamide) 
for a metastasized (lung, liver, lymph nodes) germ cell 
tumor of the testis. Conclusion: Further clinical research 
in order to better define risk factors for developing ARDS 
in this patient population as well as novel strategies for 
the prevention and treatment of ARDS in those patients 
are necessary.
Introduction
Since the introduction of cisplatin, platin-based combination 
chemotherapy has evolved as a standard of care for patients 
with advanced germ cell cancers [1, 2]. Most of these – often 
young and otherwise healthy – patients can be cured, even 
if distant metastases already have occurred. However, for 
patients with poor prognostic features, e.g. those within the 
‘poor-risk’ subgroup according to the International Germ Cell 
Cancer Collaborative Group (IGCCCG), the 5-year survival 
rate is still about 50% only. To date, only case reports or small 
retrospective single-center case series (e.g. from the ‘Institut 
Gustave Roussy’) have reported a ‘tumor-associated’ acute 
respiratory distress syndrome (ARDS) in patients with non-
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seminomatous germ cell tumors and lung metastases [3–5]. 
Some authors also hypothesized a possible aggravation of 
acute pulmonary failure by chemotherapy-induced/-associ-
ated inflammatory processes and tumor lysis [5]. Currently, 
no evidence-based prevention concepts or specific treatment 
options are defined for such a high-risk subgroup of patients 
who are at risk for developing ARDS after initiation of sys-
temic cisplatin-based chemotherapy [2].
Case Report
This case report presents a 19-year-old male patient with a metastatic 
non-seminomatous germ cell tumor of the testis, who was admitted to our 
center in April 2008 for treatment initiation. In his history, the patient 
underwent cardiac surgery at birth (1988) for a transposition of the great 
arteries according to the Senning-Brom repair. A swelling of the left tes-
tis was noticed by the patient in April 2007, but at that time he did not 
seek medical advice. The admission to a local hospital was finally initiated 
by his general practitioner due to chest and abdominal pain. Laboratory 
analysis showed an elevated lactate dehydogenase (LDH) level (1331 
U/l), together with a considerable elevation of β-human chorionic gona-
dotropin (β-HCG) (660,000 mIU/ml). α-Fetoprotein (AFP) levels were 
found to be within the reference range (2.4 ng/ml). An observed latent 
hyperthyroidism was possibly associated with the significant elevation of 
β-HCG levels [6].
The first staging computed tomography (CT) scan showed a diffuse nod-
ular infiltration in the lungs (fig. 1), the liver and the abdominal lymph 
nodes, and some of the masses showed radiographic signs of necrosis. At 
presentation, the clinical pulmonary function of the patient was stable 
(no dyspnea, SO2 without oxygen 96%), and thus a left-sided inguinal or-
chiectomy was performed on the day of admission; the next day (about 
18 h later), systemic chemotherapy using the PEI regimen (cisplatin, 
etoposide, ifosfamide) was initiated [1, 2]. Due to the massive tumor infil-
tration of the lung, no bleomycin was included in the combination chemo-
therapy regimen [2]. The final diagnosis was a stage III C (according to 
the American Joint Committee on Cancer (AJCC) classification) non-
seminomatous germ cell cancer of the left testis. Histologically and immu-
nohistologically, the resected specimen (diameter 14 cm) showed a mixed 
germ cell tumor with predominant features of chorion carcinoma but also 
with features of mature teratoma. According to the IGCCCG classifica-
tion, the patient was allocated to the ‘poor-risk’ prognostic subgroup.
Only 2 days after initiation of chemotherapy, the patient rapidly devel-
oped a partial respiratory insufficiency together with hemoptysis and was 
therefore admitted to the intensive-care unit (ICU). On ICU admission, 
the patient showed an SaO2 of 92% at an oxygen flow rate of 9 l/min via 
face mask, the blood pressure was 140/55 mm Hg, and the heart rate was 
64/min. At that time point, the patient was afebrile, showed only mild 
 elevation of C-reactive protein (CRP) levels (3.7 mg/dl, reference range 
< 0.5 mg/dl) and an interleukin (IL)-6 level of < 2.0 pg/ml. Immediate em-
piric antibiotic treatment with piperacillin and tazobactam was begun. We 
initiated non-invasive continuous positive airway pressure (CPAP) venti-
lation, but due to respiratory exhaustion the patient had to be intubated 
1 day after ICU admission. Chest X-ray showed diffuse infiltrates over 
both lungs, which were interpreted as lung metastases, possibly also ac-
companied by pulmonary lymphangiosis carcinomatosa. A broncho-
 alveolar lavage after intubation showed no typical signs of infection or of 
active pulmonary bleeding; a broad diagnostic microbiological screening 
was negative for bacteriology, mycology and virology (testing for her-
pes simplex virus (HSV), varicella zoster virus (VZV), cytomegalovirus 
(CMV) and adenovirus). Repeated aspergillus galactomannan antigen 
tests were negative. While the patient was receiving mechanical ventila-
tion, we subsequently completed the first cycle of systemic chemotherapy, 
and no clinical or laboratory sings of a tumor lysis syndrome occurred.
1 day after completion of PEI, the patient developed fever up to 40 °C 
and a rise in CRP levels (up to a maximum of 31 mg/dl) was observed. 
Corresponding IL-6 levels rose up to a maximum of 713 pg/ml; the pro-
calcitonin level was 0.9 ng/ml (reference range < 0.5 ng/ml). Parallel to 
the development of fever, the patient rapidly required a maximally in-
vasive mechanical ventilation (positive end-expiratory pressure (PEEP) 
levels up to 22 cm H2O, FiO2 100%) in order to achieve a paO2 > 60 mm 
Hg. Clinically, the diagnosis of an ARDS was made although the typical 
radiological signs of ARDS were not present, most probably due to the 
pre-existing lung metastases (fig. 2). The patient showed no signs of sepsis 
(low procalcitonin levels, normal coagulation parameters, no severe im-
pairment in renal and hepatic function); thus, an extrapulmonary etiology 
for the ARDS was rather unlikely. A ventilator-associated pneumonia 
was ruled out due to negative microbiological findings on broncho-alveo-
lar lavage. Nevertheless, the antibiotic treatment was empirically changed 
to meropenem, vancomycin, caspofungin and aciclovir. Invasive hemo-
dynamic monitoring – with the use of a transpulmonary thermodilution 
technique (PiCCO® technology; Pulsion Medical Systems, Munich, Ger-
many) – found a cardiac index (CI) of 3.5 l/min/m2 (reference range 3.0–
5.0 l/min/m2), a systemic vascular resistance index (SVRI) of about 1800 
dyn∙s∙cm–5∙m2 (1700–2400 dyn∙s∙cm–5∙m2) and an extravascular lung water 
index (ELWI) of 18 ml/kg (3.0–7.0 ml/kg). The ELWI subsequently rose 
up to a maximum of 30 ml/kg on the day before the death of the patient.
Despite the use of a lung-protective biphasic positive airway pressure 
(BIPAP®) ventilation, the ARDS remained unresolved and the patient 
developed severe hypoxemia within a few days only (pO2 44 mm Hg 
under inverse-ratio ventilation with FiO2 100% and PEEP 22 cm H2O). 
Additional high-dose steroid treatment at a dosage of 2 × 1000 mg pred-
nisolone had no positive effect on the ongoing respiratory failure. The 
use of a pre-emptive continuous veno-venous large-volume hemofiltra-
 
Fig. 1. Bilateral 
lung metastases on 
a staging CT scan of 
the chest performed 
before the start of 
PEI chemotherapy.
 
Fig. 2. Chest X-ray 
with signs of ARDS 
(‘white lung’) 2 days 
ante mortem.
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tion (initiated in order to achieve a negative volume balance and possibly 
remove pro-inflammatory cytokines) also had no effect on the progres-
sion of ARDS.
10 days after initiation of chemotherapy, the β-HCG level increased up 
to 858,000 mIU/ml (without laboratory signs of a tumor lysis syndrome). 
Assuming an expected median half-life for β-HCG of about 3 days [7], we 
thus furthermore observed no early biochemical treatment response. In 
this context, and based on the underlying malignant disease as well as the 
rapid progression and therapy resistance of the ARDS, we decided not to 
use an extracorporeal lung assist (e.g. extracorporeal membrane oxygena-
tion, ECMO) in our patient. He died 10 days after ICU admission due 
to refractory hypoxemia caused by a ‘tumor-associated’ ARDS, possibly 
 aggravated by a chemotherapy-associated inflammatory process.
Discussion
In 1990, a first case report of a ‘tumor-associated’ ARDS in 
a 32-year old patient with pulmonary metastasized chorion 
carcinoma of the testis was published by McGowan and col-
leagues [3]. 4 years later, a group from the ‘Institut Gustave 
Roussy’ published the first retrospective case series of 11 pa-
tients with – what they called – ‘super-high-risk germ-cell tu-
mors’; all of these patients suffered from non-seminomatous 
germ cell cancers and had a high tumor load in the lungs or 
the mediastinum [4]. Each of these 11 patients experienced 
ARDS during chemotherapy and required mechanical ven-
tilation; nevertheless, all patients died rapidly within 35 days 
from the start of chemotherapy. The authors of this case se-
ries hypothesized a multifactorial etiology (consisting of bulky 
disease of the chest, secondary infections and interstitial pul-
monary fibrosis) for the acute pulmonary failure observed in 
their patients [4].
To date, it remains unclear whether chemotherapy-associated 
processes may also be involved in the pathogenesis of these 
‘tumor-associated’ ARDS cases. A recent case series from 
Kirch et al. [5] reported 16 patients with non-seminomatous 
germ cell tumors and lung metastases who were admitted to 
the ICU for respiratory distress. In this patient cohort, 9 pa-
tients (56%) developed ARDS requiring mechanical ventila-
tion within a median of 2.5 days only after the initiation of 
chemotherapy. All but one of the patients requiring invasive 
ventilation died; none of these patients had received a bleo-
mycin-containing regimen. The only predictor of intubation in 
this patient population was the initial paO2 on room air upon 
ICU admission (with all patients having a paO2 < 70 mm Hg 
subsequently developing fatal ARDS). The authors of this 
small retrospective study concluded that not only the high 
pulmonary tumor load represents a major factor in the ARDS 
pathogenesis, but possibly an aggravation of the respiratory 
failure is – also with regard to the correlation in time – chemo-
therapy associated. Chemotherapy-induced inflammation and 
local tumor lysis could result in an enormous cell death and 
a high release of cytokines that would ultimately result in an 
ARDS at the organ level.
In the patient reported here, we also observed a clear correla-
tion between the start of chemotherapy and the development 
of respiratory distress requiring intubation only 3 days after 
initiation of treatment (using the non-bleomycin-containing 
chemotherapy regimen PEI). Despite maximal treatment 
efforts, the patient died due to progressive ARDS and sub-
sequent hypoxemia.
Based on the data discussed above, a certain subgroup of germ 
cell tumor patients with lung metastases – those who require 
intubation and mechanical ventilation – may have a dismal 
prognosis. Thus, prevention strategies are urgently needed in 
order to improve the outcome and to avoid the development 
of ARDS in these patients. A possible new approach could 
be the introduction of a low-dose or short-course, ‘pre-phase’ 
chemotherapy protocol for such a high-risk subgroup, for ex-
ample analogous to the current standard of care for patients 
with aggressive non-Hodgkin’s lymphoma and a high tumor 
load [8]. Such an approach was presented by Fizazi and col-
leagues at the American Society of Clinical Oncology (ASCO) 
meeting in 2007: Their small retrospective single-center study 
included 25 patients with lung metastases from non-semino-
matous germ cell cancer and dyspnea or a paO2 < 80 mm Hg 
who were treated between 1980 and 2006 at their institution 
[9]. The subgroup of patients that received initial chemother-
apy with a ‘full-dose’ chemotherapy regimen (1980–1997, n 
= 15) showed an ARDS incidence of 87% and a ‘long-term 
survival rate’ of 27%. In contrast, patients treated after 1997 
received initial chemotherapy with a 3-day reduced induc-
tion regimen of etoposide and cisplatin; in this population 
(n = 10) the ARDS incidence was 30%, and 40% of the pa-
tients were long-term survivors. However, mostly due to the 
lack of prospective data from well-defined controlled clinical 
trials, the current European Germ Cell Cancer Consensus 
Group (EGCCCG) guidelines only recommend that ‘…VIP 
may be preferred over PEB to avoid a possible bleomycin-
induced lung injury in patients with compromised pulmonary 
function’ [2]. Additionally, patients with an extensive disease 
may benefit from a brief-course or reduced-dose chemothera-
py before full-dose chemotherapy is started [2]. Thus, there is 
an urgent need for clinical research in this field, first in order 
to better characterize the subgroup of patients that is at risk 
for the severe complication of a ‘tumor-associated’ ARDS 
and second to develop an evidence-based, internationally ac-
cepted ‘standard-of-care’ treatment protocol for those high-
risk patients.
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